Latest Breaking News On - Yoshihiko tomita - Page 1 : comparemela.com

ASCO GU 2023: Nivolumab plus Cabozantinib vs Sunitinib for First-Line Treatment of Advanced RCC: 3-Year Follow-up from the Phase 3 CheckMate 9ER Trial

ASCO GU 2023: Nivolumab plus Cabozantinib vs Sunitinib for First-Line Treatment of Advanced RCC: 3-Year Follow-up from the Phase 3 CheckMate 9ER Trial
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.

United statesSan franciscoSaby georgeAmishi yogesh shahCarlosh barriosHoward gurneyBernard escudierCamillo portaJens bedkePeter wangThomas powlesMaria teresa bourlonZachary klaassenViktor fedorovMauricio burottoYoshihiko tomita

AUA 2022: Development of Patient-Derived Kidney Cancer Organoid; Application to Drug Screening Models and Its Challenges

AUA 2022: Development of Patient-Derived Kidney Cancer Organoid; Application to Drug Screening Models and Its Challenges
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.

United statesNew orleansYoshihiko tomitaDakira kazamaVladimir bilimDepartment of urologyUniversity of california irvineAmerican urological associationAmerican urological association annual meetingDivision of molecular oncologyUrological association annual meetingMolecular oncologyNiigata university graduate schoolDental sciencesCalifornia irvineUrological association